The Day I Met Martin Shkreli: Inside The Biotech-Saving Deal For A Tropical Disease Drug
It was 10 days before Christmas, and Stephen Hurst had visions in his head of Martin Shkreli, the poster child of the drug industry's pricing problems.
Hurst is the CEO of Savant HWP Inc. — the "HWP" stands for health, wellness and prevention — a small San Carlos company that controlled U.S. rights for a drug called benznidazole. He was on his way to the New York office of Shkreli, who in November had hedged his way into control (and the CEO job) at KaloBios Pharmaceuticals Inc.
Hurst is the CEO of Savant HWP Inc. — the "HWP" stands for health, wellness and prevention — a small San Carlos company that controlled U.S. rights for a drug called benznidazole. He was on his way to the New York office of Shkreli, who in November had hedged his way into control (and the CEO job) at KaloBios Pharmaceuticals Inc.